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Plasma levels for insulin-like growth factor-I (IGF-I) 
steadily increase in female rats between 20 and 40 d of 
life, and this increase is intimately related to the well- 
known growth spurt occurring at this age. Since spe- 
cific actions of IGF-I related to sexual function have 
been described at the ovarian and hypothalamic levels, 
an endocrine role of rising circulating IGF-I levels 
during sexual maturation cannot be excluded. There- 
fore, the impact of adult-type plasma IGF-I levels dur- 
ing the juvenile age, on body weight (BW) gain, growth 
of several organs, sexual development, and fertility has 
been evaluated. Female Sprague-Dawley rats were 
infused with rhlGF-I (2 and 4 pg/g BW/d, using Alzet 
minipumps), between 20 and 41 d of life. When infus- 
ing 2 tag/g BW/d, plasma levels for IGF-I were increased 
1.5- to 2-fold over controls at all ages studied. They 
were further increased with the higher dosage, but only 
after 35 d of age. Plasma levels for insulin-like growth 
factor binding protein (IGFBP)-I to -3 were clearly 
increased. BW gain was significantly increased, but 
only with the higher dosage. Tail length was never 
modified. In contrast, a growth acceleration for spleen, 
kidneys, adrenals, and ovaries was observed with both 
dosages. The ovarian weight of treated animals 
represented approx 140% of control animals with 
the 4 lag/g BW/d dosage. Histology of the enlarged 
ovaries did not reveal any abnormalities. No meaning- 
ful modification of the timing of vaginal opening was 
observed, and fertility was not compromised by previ- 
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ous rhlGF-I infusion during the 20-41 d age period. In 
summary, early exposure to increased (adult-like) 
plasma IGF-I levels did not modify BW gain or tail 
length, but affected the development of spleen, kidneys, 
adrenals, and ovaries. Exposure to supraphysiological 
plasma IGF-I levels (>1200 ng/mL), accelerated BW 
gain and increased the weight of all organs studied. No 
signs of precocious sexual maturation were seen and 
fertility was normal. In conclusion, prematurely 
increased plasma IGF-I levels affected somatotropic 
parameters, but not the onset of sexual function. 
Key Words: Sexual maturation; puberty; insulin-like 
growth factor-I (IGF-I); insulin-like growth factor bind- 
ing proteins (IG F B Ps); gonadotropi n-releasi ng hormone 
(GnRH); ovary; fertility; female rats. 
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Introduction 
Plasma levels of insulin-like growth factor-I (IGF-I) 
steadily increase during the juvenile period in both male 
and female rats (1,2), and this increase is intimately related 
to the acceleration ofgrowth at this age. Indeed, any experi- 
mental situation with reduced growth rate is linked to 
reduced IGF-I secretion (2-5). In contrast, it is still unclear 
whether this acceleration of IGF-I secretion during the 
juvenile period can affect he course of sexual maturation. 
The authors have recently demonstrated that inhibition of 
growth hormone (GH) secretion by passive immunization 
of rat growth ormone-releasing factor (GRF), which mark- 
edly reduced IGF-I secretion, produced an important delay 
in growth, but no significant effects on the timing of sexual 
maturation and fertility (2). Thus, ifa deficit in IGF-I secre- 
tion is of no consequence, it is not yet known whether adult- 
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type or supraphysiological plasma IGF-I levels imposed 
during the juvenile age could affect ovarian development 
or more generally, the onset of sexual maturation. A stimu- 
latory effect of increased IGF-I can be postulated either at 
the hypothalamic orthe gonadal level. Studies mostly per- 
formed in in vitro models have indicated that IGF-I can 
influence gonadotropin-releasing hormone (GnRH) release 
(6, 7), possibly favoring the pubertal increase in GnRH 
release (6). However, the demonstration f such phenom- 
enon in in vivo situations is still lacking. A large body of 
knowledge demonstrating the existence of paracrine-type 
of actions of IGF-I in the ovary, with the involvement of 
insulin-like growth factor binding proteins (IGFBPs) is 
available (8,9), but evidence for an endocrine role of circu- 
lating IGF-I on ovarian development and function is scarce 
and often controversial (10-13). 
It has been shown that treatment with IGF-I can promote 
growth in hypophysectomized rats (14-17), or in rat or 
mouse models with low or absent GH secretion (3). Using 
an appropriate dosage, IGF-I treatment inGH-deficient rats 
allowed to restore an almost normal growth rate, but unex- 
pectedly induced accelerated growth rate of several organs, 
possibly leading to organomegaly, particularly spleen, kid- 
neys, and adrenals (3). Transgenic mice with enhanced 
expression of the IGF-I gene also exhibit organomegaly 
(18,19). Recently, treatment with rhlGF-I of severely growth- 
retarded patients with GH receptor defect (Laron-type dwarf- 
ism) has been introduced (20). Concerns have been expressed 
about adverse ffects of exogenously administered IGF-I on 
gonadal growth and/or function as well as nonproportional 
growth of other organs. The authors, therefore, valuated the 
impact of elevated IGF-I plasma concentration starting at 
20 d of life on growth and initiation of sexual function in 
female rats. Constant infusion of IGF-I was used in order to 
prematurely raise plasma levels to normal adult levels, and by 
using a larger dosage, to supraphysiological levels. It has been 
demonstrated that ovarian growth can be influenced by circu- 
lating IGF-I since increased plasma IGF-I levels during the 
juvenile period produced a small but significant increase in 
ovarian weight at 41 d of life without modifying the timing of 
sexual maturation or fertility. 
Results 
A constant infusion of IGF-I was imposed between 20 
and 41 d of life. Except for the few rats used for the fertility 
test, animals were sacrificed at the end of pump capacity 
while still under the influence of infused IGF-I. At sacri- 
fice, all pumps were found to have delivered the expected 
volume of IGF-I solution. 
Effects of lGF-I Infusion 
on Growth and the Somatotropic Axis 
Plasma IGF-! Concentration 
Plasma IGF-I concentrations steadily increased between 
20 and 41 d in untreated female rats, as illustrated with a full 
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Fig. 1. Pattern of changes between 20 and 41 d of life in body 
weight (BW) and plasma IGF-I concentration in Sprague-Dawley 
female rats either eceiving arhlGF-I infusion of 2 (A), or 4 ( t )  
~g/g BW/d using Alzet minipumps, starting at 20 d of life as 
indicated, or untreated (O). Mean + SE. No significant differ- 
ences in BW were observed between untreated rats and rats 
receiving 2/ag IGF-I/g BW/d; BW of rats infused with 4 ktg/g 
BW/d were different from controls starting at 33 d of life, as 
indicated. Plasma IGF concentrations of IGF-I-infused rats were 
highly significantly increased above control values. A significant 
difference in plasma IGF-I between rats receiving 2 and 4 gg/g 
BW/d, was observed at 23 and 41 d, as indicated. Rats from 
series #2:10 rats per point; other data presented inTable 1. 
line in Fig. 1. Infusion with 2 ~tg IGF-I/g BW/d signifi- 
cantly increased plasma IGF-I levels at all ages, but the 
achieved absolute levels were lower at younger than older 
ages. In the IGF-I-infused rats presented inFig. 1 and Table 
1, plasma IGF-I increased from approx 700 ng/mL at 23 d 
to 1000 ng/mL at 35 d, as shown with filled triangles; there- 
after, a further increase occurred with plasma IGF-I levels 
reaching approx 1500 ng/mL at 41 d, consistent with 
the plasma levels achieved in the other series with the same 
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Table 1 
Treatment of Immature Female Rats with a Constant Infusion of rhIGF-I Between Day of Life 20 and 41, 
as Illustrated in Fig. 1 (Series # 1)---Effects Seen at Sacrifice at Day of Life 41 on Growth and Somatotropic Parameters 
IGF-I,/.tg/g/d 
Controls 2 4 AOV, p 
Growth parameters 
Body wt, g 168 + 4 173 + 4 189 + 4*** <0.005 
Tail length, cm 14.9 + 0.2 14.6 + 0.2 14.9 + 0.2 NS 
Pituitary wt, mg 7.65 + 0.39 8.74 + 0.50 9.45 + 0.50* <0.05 
mg/100g BW 4.49 + 0.18 4.95 + 0.19 4.88 + 0.22* NS 
Spleen wt, mg 706 + 38 1044 + 37*** 1428 + 115"** <0.001 
mg/100 g BW 415 + 18 597 + 25*** 740 + 525*** <0.001 
Kidney wt, g 1.59 + 0.04 1.92 + 0.05*** 2.31 + 0.06*** <0.001 
g/100 g BW 0.93 + 0.01 1.09 + 0.02*** 1.20 + 0.02*** <0.001 
Heart wt, mg 714 + 20 734 + 22 822 + 23** <0.005 
mg/100 g BW 406 + 9 418 + 6 427 + 6* NS 
Adrenal wt, mg 41.4 + 1.4 47.7 + 2.6* 50.6 + 1.7"** <0.01 
mg/100 g BW 24.3 + 0.6 26.8 + 1.0" 26.3 + 0.7* <0.05 
Somatotropic axis 
Plasma IGF-I, ng/mL 976 + 40 1489 + 67*** 1913 + 96*** <0.001 
Plasma GH, ng/mL 11.7 + 4.8 26.2 + 4.9 24.8 + 6.3 NS 
Pituitary GH, pg 126 + 15 174 + 17" 196 + 14"** <0.025 
Plasma IGFBP-1 100 + 13 147 + 21 187 + 13"** <0.005 
Plasma IGFBP-2 100 + 15 149 + 26* 177 + 19"* <0.05 
Plasma IGFBP-3 100 + 11 160 + 20* 192 + 22** <0.005 
Plasma IGFBP-4 100 + 7 83 + 7 86 + 7 NS 
Reproductive parameters 
Ovarian wt, mg 40.7 + 3.6 50.9 + 3.1" 57.3 + 3.6** <0.01 
mg/100 g BW 23.8 + 1.9 29.0 + 1.6 29.8 + 1.7" <0.05 
Uterine wt, mg 196 + 17 226 + 16 253 + 20 NS 
mg/100 g BW 115 + 9 128 + 7 132 + 10 NS 
Vaginal opening, d 38.6 + 0.8 37.2 + 0.8 38.2 + 0.9 NS 
Mean + SE; 10 rats per group; significance, analysis of variance (AOV) withp values indicated for 2,27 degrees of freedom; 
plasma IGFBPs expressed in percent value of controls. 
*p < 0.05, **p < 0.01, ***p < 0.001 with respect to untreated controls. 
dosage at the same age (1404 + 41 ng/mL, Table 2). The 
pattern of increased plasma levels for IGF-I was similar for 
the higher dosage (4 p.g/g BW/d). There was a significant 
difference between the two dosages at 23 d, then no differ- 
ence between 25 and 35 d, both dosages generating similar 
adult plasma levels (~1000 ng/mL). After 35 d, a marked 
increase in plasma levels was seen for both dosages, and 
supraphysiological plasma levels were obtained with a clear 
difference at 41 d between the two dosages. 
Pituitary GH Content and Plasma GH Levels 
A dose-dependent, significant increase in pituitary GH 
content was seen in the series presented in Table 1. The 
same trend, although not significant, was found in the 
other series. There was no difference in plasma GH lev- 
els at sacrifice in control or IGF-I-treated rats (Table 1), 
and evidence for GH peaks was obtained in the group 
of  rats receiving 4 ktg/g BW/d since three values above 
50 ng/mL were measured. These elevated GH values peak 
against a possible inhibition of GH secretion by increased 
circulating IGF-I. 
Plasma IGFBPs Concentration 
Analysis of plasma IGFBPs in the series presented in 
Fig. 1 indicated that infusion of  IGF-I produced increases 
in IGFBP-1 to -3 of  a similar amplitude, whereas no 
increase was seen for IGFBP-4. The increase in IGFBP-3 
corresponded to 160 + 20% of controls with the 2 ~g/g BW/d 
dosage, and 192 + 22 %, with the 4 p.g/g BW/d dosage at 
41 d (Table 1). 
Body Weight Gain and Tail Length 
No significant effect on BW gain was observed with 
infusion of 2 ~ IGF-I/g BW/d. With the higher dosage (4 p.g/ 
g BW/d), BW gain was significantly increased over con- 
trois starting at 33 d (p = 0.002), and remained so until 
41 d (p < 0.001, Fig. 1, lower panel). In both series, no 
effects of the IGF-I infusion were observed on tail length as 
measured at 41 d. 
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Table 2 
Treatment of Immature Female Rats with a Constant Infusion 
of rhIGF-I Between Day of Life 20 and 41 (Series #2)--Effects on Sexual Maturation and Fertility 
Controls IGF-I, 2 pg/g BW/d Significance, p 
Data at 41 d 
Plasma IGF-I, ng/mL 1017 + 25 1404 + 41 <0.001 
Body wt, g 170 + 3 176 + 5 NS 
Pituitary wt, mg 7.47 + 0.42 8.02 + 0.49 NS 
mg/100 g BW 4.41 + 0.19 4.55 + 0.19 NS 
Spleen wt, mg 574 + 44 824 + 23 <0.001 
rag/100 g BW 333 + 20 469 + 18 <0.001 
Ovarian wt, mg 42.4 + 3.2 56.4 + 2 0.005 
mg/100 g BW 24.9 + 1.7 32.0 + 1 0.006 
Vaginal opening, d 36.2 _+ 0.4 37.8 + 0.6 0.031 
Fertility 
Number of pups 13.2 + 0.8 12.5 + 0.8 NS 
Pup wt, g 7.00 + 0.07 7.06 + 0.10 NS 
Mean + SE; 8 rats per group sacrificed at the end of pump capacity at 41 days of life, 6 rats per group used 
for the fertility test; assessment ofday of vaginal opening done with all rats (14 rats per group). 
Weight Gain of Nonreproductive Organs 
In contrast to the absence of any large changes in BW 
gain, striking dose-dependent ffects of infused IGF-I were 
seen on the growth of spleen, kidneys, heart, and adrenals 
(Tables 1 and 2). For spleen, kidney, and adrenals, this 
effect was also seen if organ weight was expressed per 
100 g BW. The effects on the weight gain of the spleen were 
the greatest, followed by kidneys and adrenals, and were 
present at both dosages studied. The 3-wk IGF-I infusion at 
4 gg/g BW/d produced a doubling of spleen weight. The 
increase in spleen weight was clearly present in each 
animal, therefore, representing an internal marker for the 
effect of IGF-I. Histological examination ofenlarged spleen 
did not reveal any abnormalities, but rather an homoge- 
neous enlargement of this tissue. 
Effects of lGF-I Infusion on the Reproductive Axis 
Weight Gain of Reproductive Organs 
Treatment with IGF-I at the dose of 2 pg/g BW/d did not 
affect pituitary growth, but a significant increase was seen 
with the 4 pg/g BW/d dosage not present ifpituitary weight 
is expressed in function of BW (Table 1). IGF-I infusion 
produced a significant, dose-dependent i crease in ovarian 
weight (Tables 1 and 2). With the 4 ~g/g BW/d dosage, 
ovarian absolute weight of treated rats represented approx 
140% of control weight and this increase was also seen if 
expressed in function of BW (Table 1). 
Ovarian Morphology 
The histological aspect of ovarian tissues for control and 
IGF-I-treated rats for the two dosages, as seen at the light 
microscopic level, is illustrated in Fig. 2. No abnormalities 
were seen in the ovaries of the treated animals, and the 
analysis of the different follicles indicated a similar stage of 
development in the three sets of ovarian tissues examined. 
The proportion of primary follicles, Graafian follicles, and 
corpora lutea assessed by inspection of a comparable num- 
ber of stained sections of ovaries originating from control 
and IGF-I-treated rats at both dosages was shown not to be 
different, as seen by a chi-square analysis (Table 3). 
Uterine Weight 
There was a moderate increase in uterine weight, but the 
analysis of variance did not indicate a dose-dependent 
increase. 
Vaginal Opening and Fertility 
One purpose of this study was to evaluate whether pre- 
maturely increased circulating IGF-I to adult levels would 
modify the timing of sexual maturation by an action at either 
the hypothalamic orgonadal level. In series # 1 that included 
both IGF-I dosages, there was no difference in the timing 
of vaginal opening (Table 1). In series #2, a small but sig- 
nificant delay of 1.6 d in vaginal opening was observed 
(Table 2). In two other series performed in similar condi- 
tions (2 gg IGF-I/g BW/d), vaginal opening took place at 
36.5 + 1.0 d in treated animals vs 37.3 + 0.4 d in controls in 
one series and 38.5 + 1.0 d vs 37.3 + 0.4 d, in the other series 
(data not shown). Fertility was tested in half of the rats 
presented in Table 2. Alzet pumps were left in place, and 
mating occurred at 50 d of life. The outcome of mating and 
gestation was not different between control and IGF-I- 
treated rats. A vaginal plug was seen for all rats. Neither the 
number of pups, nor the weight of pups were different 
between control and IGF-I-treated rats (Table 2). 
Discussion 
The aim of this study was to evaluate the effects of 
increased plasma IGF-I levels during the juvenile period of 
the female rat, defned as days of life 20-35 (21), on growth 
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Fig. 2. Structure o fovarian tissues studied at the light microscope 
level in a control rat (A) and in representative rats treated with 2 
(B), and 4 (C) gg IGF-I/g BW/d between 20 and 41 d. The ovarian 
slices were treated and stained according to the Masson- 
Goldner's trichrome method, as described in the Method section. 
PF, primary follicle; GF, Graafian follicle; CL, corpus luteum. 
Scale bar represents 200 pro. 
and developmental aspects of sexual function. Since abnor- 
mally elevated plasma levels of IGF-I have been shown to 
increase the size of several organs (3,18,19), special atten- 
tion was given to possible ffects oflGF-I on the growth of 
both reproductive and nonreproductive organs during 
development. I  has recently been demonstrated that mark- 
edly reduced IGF-I plasma levels, secondary to the inhibi- 
tion of GH secretion by passive immunization against rat 
GRF starting at 15 d of life, drastically reduced growth rate, 
Table 3 
Treatment of Immature Female Rats with a Constant Infusion 
of rhlGF-I Between Day of Life 20 and 41-  
Distribution of Primary Follicles, Graafian Follicles, 
and Corpora Lutea Expressed in Percentage of Observed Structures 
IGF-I, pg/g/d 
Controls 2 4 
Primary follicles 35.0 % 28.5 % 34.1% 
Graafian follicles 35.8 % 41.4 % 31.1% 
Corpora lutea 29.1% 30.1% 34.8 % 
Number of 
counted structures 120 133 161 
No significant difference in distribution between treatment 
groups (chi-square test, a = 0.05). 
but did not disturb the onset ofestrous cycles, thus indicat- 
ing that low plasma IGF-I levels do not prevent sexual 
maturation and fertility (2). The authors found it as impor- 
tant to address the question whether increased, rather than 
decreased, plasma IGF-I levels would affect sexual matu- 
ration, possibly producing precocious puberty. This issue 
is important for the pediatric endocrinologists who treat 
GH-resistent patients with IGF-I. 
We show that chronically elevated plasma IGF-I levels 
generated by constant infusion f IGF-I at two dosages pro- 
duced the expected differential cceleration oforgan growth 
seen previously in studies performed with adult animals, with 
a significant increase in ovarian weight at 41 d of life. In 
contrast, he IGF-I infusion either accelerated the timing of 
sexual maturation nor did it alter fertility later on. 
The rationale of this study was to impose plasma IGF-I 
levels in young female rats comparable to those seen in 
sexually mature animals, thus raising these levels from 
approx 300 to 1000 ng/mL starting at 20 d of life. The 
authors found that the infusion of 2 gg/g BW/d generated 
lower plasma levels in younger animals, 600-700 ng/mL at 
27 d of life, than later in older animals at 35 d of life, when 
plasma values clearly became above normal adult levels 
(> 1000 ng/mL). Increasing the dose to 4 gg IGF-I/g BW/d 
did not significantly increase circulating plasma IGF-I lev- 
els over those observed with the lower dosage during the 
25-35 age range, pointing to some saturation mechanisms 
that could be related to the availability of IGFBPs at this 
young age. A dose-dependent difference in plasma IGF-I 
levels was only seen at 41 d. At this age, there was a good 
parallelism between achieved plasma IGF-I levels and the 
observed increase in circulating IGFBPs. Obviously, the 
achieved plasma IGF-I levels in infused animals depend 
upon several parameters: the IGF-I dosage used, a possible 
decrease in endogenous IGF-I secretion secondary to 
reduction in GH secretion, an IGF-I-stimulated increase in 
circulating IGFBPs, and possible changes of clearance rate 
as a result of other causes than IGFBPs concentration. 
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The biological action of IGFs is closely modulated by 
the presence of IGFBPs in the circulation (5,22,23). The 
induction of IGFBP-3, the most abundant circulating 
IGFBP that mainly conditions the half life for IGF-I, is 
hormonally regulated, GH being the most important 
regulator oflGFBP-3 synthesis (5). However, IGF-I itself 
can also induce the production oflGFBP-3 in the rat (5,24). 
IGF-I treatment of hypophysectomized, or protein- 
deprived rats with low or absent GH can markedly increase 
IGFBPs (5,25). The ability oflGF-I to trigger the synthesis 
of its own IGFBPs has also been demonstrated in vitro (26). 
This study confirms that IGF-I treatment induces ynthesis 
and release of large amounts of principally IGFBP-3, but 
also IGFBP-1 and -2. 
Various tudies have demonstrated that IGF-I can inhibit 
GH secretion at the pituitary level, as seen with pituitary 
cells in culture (27,28), with permanent cell lines such as 
GH 3 (29), or with pituitary explants in culture (30,31). The 
available published in vivo studies are more difficult to 
interpret since systemic administration of IGF-I would 
certainly act at the pituitary level to reduce GH release, so 
that any additional action at a higher level is less easily 
identified. Thus a central administration flGF-I using the 
intracerebroventricular route is needed, not necessarily 
representing a peripheral ction oflGF-I (32). Tannenbaum 
et al. have shown that icv administration f IGF-I and -II 
could interact with the hypothalamic regulation of GH 
release, but apparently, IGF-I alone is unable to act cen- 
trally to inhibit GH secretion (33,34). Thus, the feedback 
action of circulating IGF-I is most likely exerted at the level 
of pituitary somatotrophs. 
It was anticipated that the authors' IGF-I infusion para- 
digm would reduce GH secretion. Indeed, in a preliminary 
study, they observed a reduction of the pulsatile release of 
GH in some of the young rats receiving 2 lag IGF-I/g BW/d. 
In the present study the authors demonstrate increased 
pituitary GH content in IGF-I-treated rats consistent with a 
buildup phenomenon suggesting a decrease inGH release. 
However, with both dosages, normal to elevated plasma 
GH levels were measured at sacrifice, whereas plasma 
IGF-I levels were equal to or above 1400 ng/mL. This is 
negative vidence that circulating IGF-I at this concentra- 
tion abolish GH secretion. In a more recent study, an infu- 
sion of 8 lag IGF-I/g BW/d in 40-d-old rats generating 
plasma IGF-I levels of about 2000 ng/mL was shown to 
consistently inhibit pulsatile GH release as seen over a 24-h 
collection period (V. d'All6ves, N. M. Gruaz, A. Skottner, 
and M. L. Aubert, in preparation). Thus it appears that 
inhibition of plasma GH by IGF-I is a dose-related phe- 
nomenon and is probably present only with dosages above 
4 lag/g BW/d. 
No effect of infused IGF-I was seen on BW again in rats 
receiving 2 lag IGF-I/g BW/d roughly creating the physi- 
ological plasma levels of the adult female rat. Treatment 
with IGF-I has previously been shown to reestablish growth 
in hypophysectomized rats (3,14-16), and there has been 
much debate whether such treatment could restore normal 
growth rate. It now appears that the choice of dosage is 
most important and Guler et al. have shown that 300 pg/d 
(or approx 2.5 p,g/g/d) was necessary to achieve this goal 
(16). In mutant Dwarf rats, a dosage of 180 pg/d (1 p.g/g/d), 
only partially restored normal growth rate (3). It is possible 
that simultaneous administration f GH and IGF-I might be 
more appropriate to promote growth (35), probably by 
minimizing the lack of GH secretion because of the poten- 
tial inhibition imposed by exogenous IGF-I. In this study, 
the dose of 4 pg IGF-I/g BW/d generated supraphysio- 
logical plasma levels during the last 5 d of treatment and 
significantly increased BW gain during this period, con- 
firming that IGF-I can increase BW gain above the normal 
range. However, tail length was not affected in these 
conditions. 
IGF-I infusion during the juvenile age in the female rat 
produced a dose-dependent acceleration fgrowth of sev- 
eral organs as seen from increased weight, confirming ear- 
lier studies from one of us (3), and extending them to this 
younger age period. The most striking effect was on spleen 
weight with observed 1.5- to 2-fold increases. These 
increases are more important than corresponding BW 
increase as seen when organ weights are expressed per 
100 g BW. This is in agreement with earlier studies per- 
formed either in GH-deficient rat models (3), or transgenic 
mice overexpressing the IGF-I gene (18,19). These effects 
of IGF-I infusion on spleen weight cannot be a result of a 
nonspecific inflammatory insult resulting from implanta- 
tion of the Alzet pump, since it was previously observed 
that when using a low IGF-I dosage (0.5 p,g/g BW/d) that 
did not produce any effects, spleen weight remained nor- 
mal despite the presence of the Alzet pump (data not 
shown). One interesting novel observation i  this study 
was that IGF-I infusion produced acceleration fpituitary 
growth when using the 4 p,g/g BW/d dosage, indicating that 
IGF-I might affect growth of this organ, as alluded to in 
another study (15). Kidney weight was increased atall ages 
studied and the achieved kidney weight in treated animals 
represented approx 145% that of control values with the 
4 ~tg/g BW/d dosage. Histological examination ofkidneys 
from control and IGF-I-treated rats performed with tissues 
removed at 40 d of life did not reveal any modifications of 
the renal structure (E. Girardin, personal communication). 
Heart weight was moderately increased and only in the high 
dose group. 
One important aim of this study was to evaluate the effect 
of increased plasma IGF-! levels on reproductive function. 
It has been shown that IGF-I treatment consistently pro- 
duced an increase in ovarian weight, as seen at 41 d of life. 
In a preliminary study the authors observed no increase in 
ovarian weight at 27 and 34 d when 2 pg IGF-I/g BW/d was 
infused, starting at 20 d. The increase in ovarian weight at 
41 d was significant, but the achieved weight in IGF-I- 
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treated rats at this age did not exceed the weight generally 
seen for adult animals. Furthermore, the enlarged ovaries 
appeared completely normal histologically. Ina toxicologi- 
cal study performed by two of the authors, adult female rats 
(n = 25-30) received aily sc injections of rhIGF-I (0.4 to 
10 gg/g BW/d) for a period of 26 wk. No significant differ- 
ence in ovarian weight between controls (93 + 24 mg) and 
rats receiving 10 gg IGF-I/g BW/d (119 + 75 mg) was 
observed. Histological examination ofthe ovaries did not 
show any treatment-related pathological changes. 
The concern that increased plasma IGF-I could advance 
sexual maturation was not verified. Indeed, prematurely 
increased plasma levels for IGF-I did not modify the pace 
of sexual maturation. Onset of estrous cyclicity as seen by 
vaginal opening was not accelerated in treated animals as 
seen with two IGF-I dosages. Provided that vaginal open- 
ing is checked only once daily, the small delay of 1.6 d 
observed in one series (series #2), is close to the normal 
variation seen for this parameter (p --- 0.031). It does not 
weaken the statement that no meaningful changes were 
observed. As said, in two other series performed insimilar 
conditions (2 gg IGF-I/g BW/d), vaginal opening took place 
at the same time in IGF-I-treated and control animals. In a 
toxicological study in sexually mature female rats per- 
formed at Pharmacia inSweden, the influence of increased 
IGF-I plasma levels upon reproductive function and fer- 
tility was assessed. Daily subcutaneous treatment with 
rhIGF-I at dose levels of 0.4--10 gg/g BW/d for 15 d before 
pairing and up to day 14 after mating did not cause any 
adverse ffects on oestrous cycles, mating performance, or 
fertility (data not shown). 
The possibility that circulating IGF-I produces more 
specific endocrine effects on ovarian function than promot- 
ing organ growth remains open. The relation between cir- 
culating GH and IGF-I on the ovarian function, and action 
of locally produced IGF-I is still unclear (8, 9). A possible 
role for circulating GH at the ovarian level could be through 
the local generation of IGF-I. Potentiating effects of GH 
and/or IGF-I at the ovarian level have been advocated (8, 9). 
The existence of a well-defined intraovarian IGF system, 
involving IGF-I and II, specific receptor subtypes, and sev- 
eral populations of IGFBPs have been nicely documented 
(8,13). Apparently, the internal signaling system achieved 
by IGF-I that potentiates FSH action, is autonomous, 
specifically responding to gonadotropins, and might not 
depend upon other external influences uch as GH or 
hepatic IGF-I. Nevertheless, some evidences for a trophic 
action of GH on the ovary have been documented (10-12). 
There have been suggestions that the rising plasma lev- 
els of IGF-I could provide a stimulatory signal for the 
pubertal increase in GnRH release (6). In this situation, 
IGF-I would be able to act on GnRH neuron terminals in the 
median eminence, or possibly at perikarya if a transport 
mechanism through the blood-brain barrier is confirmed 
(36). Hiney et al. (6) showed that IGF-I (but not insulin or 
IGF-II) can increase the in vitro release in GnRH from 
incubated median eminence obtained from 30-d-old female 
rats. The authors have shown that low IGF-I plasma con- 
centrations in GH-deprived rats do not modify the hypotha- 
lamic drive of sexual function in the rat (2). An action for 
IGF-I at the hypothalamic level cannot be excluded as dis- 
cussed in a recent report (7), but appears unlikely. 
In conclusion, treatment of immature female rats with 
IGF-I significantly modified BW gain at the higher dosage 
tested and this effect could be related to the increase in 
IGFBPs that permits alonger half-life for IGF-I, thus prob- 
ably prolonging biological action. Significant biological 
action of IGF-I was seen in this study with the increase in 
weight of several organs, including ovarian weight. Despite 
the increased presence of plasma IGF-I, no major effects 
were seen on reproductive function. The normal outcome 
of gestation and delivery with rats treated uring the juve- 
nile period, or in adult rats treated chronically with higher 
IGF-I dosages, indicates that excessive presence of circu- 
lating IGF-I is not deleterious tosexual function. 
Materials and Methods 
Hormones 
Human IGF-I was produced by Pharmacia AB, Stock- 
holm, Sweden (3), and 5 or 10 mg/mL solutions were used 
to fill the Alzet minipumps. 
Animals 
Sprague-Dawley female rats were purchased from IFFA- 
CREDO (69592 L'Arbresle, France), and were received 
at 10 d of life with 10 pups per dam. They were provided 
with water and standard rat pellets ad libitum unless indi- 
cated. Room temperature was maintained between 21 and 
23~ and a 12/12 h light/dark cycle was used. Body 
weight (BW) was measured daily. All experiments were 
reviewed by the University of Geneva School of Medicine 
Ethical Committee for Animal Experimentation and 
approved by the State of Geneva Veterinary Office (autho- 
rization No. 31.1.28/459/II). 
Experimental Protocols 
Two series of rats were studied strictly using the same 
protocol. The principle was to impose adult levels of circu- 
lating IGF-I to immature rats throughout the entire juvenile 
period (20-41 d of life) and to study the effects of this 
treatment on somatic and reproductive parameters. 
Series #1 
This series included two IGF-I dosages (2 and 4 gg/g 
BW/d) for an infusion period between 20 and 41 d of life. 
Alzet pumps 2001 (200 gL capacity, 1.0 gL/h flow rate) 
were used. Pumps were filled with the 5 mg/mL IGF-I 
solution for the lower dosage and with the 10 mg/mL 
solution for the higher dosage. At 20 d, one pump was 
implanted; then at 27 d, the used pumps were removed and 
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two new pumps were implanted; at 34 d, two new pumps 
were implanted similarly. Control rats were also anesthe- 
tized and sham-operated on these days. Day of vaginal 
opening was assessed by daily vaginal inspection starting 
at 30 d of life. All rats were sacrificed at 41 d. In this series, 
a small volume of blood was collected from the tail tip of 
each rat at days of life 23, 28, 30, 35, and 37 to monitor 
plasma IGF-I concentration. Using the 5 mg/mL IGF-I 
solution to generate he 2 gg/g BW/d dosage, actual dosage 
of IGF-I based on measured BW and pump delivery was 
2.58 gg/g BW/d at 20 d, 1.51 at 27 d before pump change, 
2.80 at 28 d after inserting two pumps, 1.80 at 34 and 1.39 
at 41 d, thus resulting in a mean dosage of 1.95 + 0.09 gg/ 
g BW/d. For the 4 gg/g BW/d dosage, for which the 10 gg/ 
mL IGF-I solution was used to fill the pumps, actual dosage 
was 5.16 at 20 d, 3.01 at 27, 5.56 at 28 d after the implan- 
tation of two pumps, 3.39 at 34 d, and 2.53 at 41 d, resulting 
in a mean dosage of 3.81 + 0.20 gg/g BW/d. Rats were 
sacrificed at 41 d (10 rats per group), trunk blood was col- 
lected in chilled heparinized tubes, pituitary, and ovaries 
were quickly dissected out, weighed and frozen, other 
organs uch as kidneys and spleen were also dissected out 
but only weighed. 
Series #2 
Alzet pumps 200 L filled with the 5 mg/mL IGF-I solu- 
tion were used, resulting in a daily dose of 2 gg/g BW. As 
for the other series, one pump was implanted inthe area of 
the neck under light ether anaesthesia at 20 d of life; then 
at 27 d, the used pumps were removed and two new pumps 
were implanted, always under light ether anaesthesia. At
34 d, two new pumps were implanted similarly. Control 
rats were also anesthetized and sham-operated on these 
days. Part of the rats were sacrificed at 41 d (8 rats per 
group), as described for series # 1. The remaining rats (6 rats 
per group) were not sacrificed, the pumps were left in situ, 
and fertility was evaluated at 50 d of age, with six IGF-I- 
treated rats and five corresponding controls being left each 
with a normal male for 7 d and outcome of breeding, evaluated. 
Hormone Determinations 
Plasma and pituitary GH concentrations were analyzed 
by RIA as described earlier (37), using NIADDK-anti-rGH 
$5 and the RP-2 reference preparation. RIA for IGF-I was 
performed as described recently in detail (38) by using the 
antiserum UB 3-189 provided by Drs. L. Underwood and 
J. J. Van Wyk and a recombinant IGF-I preparation btained 
from Pharmacia, Kabi Peptide Hormones, Stockholm, Swe- 
den. Serum extraction was performed according to the 
method escribed by Breier et al. (39). This extraction tech- 
nique has been validated as providing complete removal of 
IGFBPs. The antiserum (1:10,000 final dilution) was 
incubated for 90 min at 4~ with plasma specimens (dupli- 
cates), or standard amounts of biosynthetic IGF-I (tripli- 
cates) after which radioiodinated 125I-IGF-I (15,000 cpm) 
was added. Within and between assay variance was 8 and 
17%, respectively. Minimal detectable concentration was 
5 pg/tube. 
Distribution of lGFBPs by Western Ligand Blot Analysis 
The distribution of plasma IGFBPs was performed by 
the Western Ligand Blotting technique described by 
Hossenlopp et al. (40) as described in detail recently (2). 
Briefly, plasma samples were diluted with buffer, boiled at 
95~ for 5 min, cooled and immediately applied to a 11% 
SDS-polyacrylamide g land run using a constant current 
(8 mA/gel) for about 20 h. The fractionated proteins were 
electroblotted on Immobilon membranes and after wash- 
ing, the membranes were incubated in a sealed plastic bag 
in presence of l25I-IGF-I at 4~ Radiolabeled IGFBPs were 
visualized by autoradiography and quantified using the 
program Image Quant, version 3.2. from Molecular Dynam- 
ics, on an Olivetti M 400-40 desk computer. 
Analysis of Ovarian and Spleen Histology 
Spleen and ovaries from rats treated with IGF-I and 
controls were fixed by immersion i 4% paraformaldehyde 
and stored at 4~ in the same fixative for several days. 
Tissue blocks were washed in 10% sucrose in phosphate 
buffer, pH 7.4, for up to 24 h, and cut in longitudinal plane 
using a cryostat. Fifteen ~rn sections were thaw-mounted 
on poly-L-lysine subbed glass slides and stained according 
to the procedure reported by Goldner (41). The sections 
finally mounted in Eukit were examined and photographed 
under Zeiss Axioskop microscope. The follicular matura- 
tion in control and treated animals was examined instained 
sections through the ovaries (approx 12 sections/ovary). In 
order not to count a structure twice, number of follicle was 
estimated by counting oocytes that should appear only once 
when using 15 grn section; corpus lutea were counted only 
when at maximal profile. The distribution frequency of 
observed primary follicles, Graafian follicles and corpora 
lutea was assessed and compared between groups by a 
chi-square analysis. 
Statistical Analysis 
Analysis of variance (ANOVA) was first performed to 
evaluate the overall variation due to treatment, then indi- 
vidual variations were analyzed by the Duncan's range test, 
or unpaired t-test when appropriate. 
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